February 6, 2013
Otsuka Pharmaceutical Co., Ltd.
The European Medicines Agency (EMA) Approves Aripiprazole (ABILIFY®) for the Treatment of Moderate to Severe Manic Episodes in Bipolar I Disorder in Adolescents.
Tokyo, Japan, February 6th 2013 - Otsuka Pharmaceutical Co. Ltd. announced today that the European Medicines Agency (EMA) has approved a label extension for aripiprazole for the treatment up to 12 weeks of moderate to severe manic episodes in Bipolar I Disorder in adolescents aged 13 and older.
This will be the first centrally approved indication for the treatment of moderate to severe manic episodes in Bipolar I Disorder in this age group in Europe.
"Our endeavours to bring this aripiprazole adolescent indication to market demonstrates our long-term commitment to discover and develop new treatment options for the most challenging psychiatric diseases," said Dr.Giuseppe Di Benedetto MD PhD, Senior Vice-President, Medical Affairs and Compliance, Otsuka Pharmaceutical Europe Ltd.
Aripiprazole was studied in a 30-week placebo controlled trial involving 296 children and adolescents, who met DSM-IV criteria for Bipolar I Disorder with manic or mixed episodes with or without psychotic features and had a Y-MRS score ≥ 20 at baseline. Aripiprazole was superior to placebo in change from baseline at week 4 and at week 12 on the Y-MRS total score.
The recommended dose for aripiprazole in this indication is 10mg/day administered on a once-a-day schedule without regard to meals. Treatment should be initiated at 2mg (using aripiprazole oral solution 1mg/ml) for 2 days, titrated to 5mg for 2 additional days to reach the recommended daily dose of 10 mg.
The treatment duration should be the minimum necessary for symptom control and must not exceed 12 weeks. The frequency and type of undesirable effects in adolescents with Bipolar I Disorder were similar to those in adults except for somnolence, extrapyramidal disorder, akathisia, and fatigue, abdominal pain upper, heart rate increased, weight increased, increased appetite, muscle twitching, and dyskinesia. Younger patients are at increased risk of experiencing adverse events associated with aripiprazole. Therefore, aripiprazole is not recommended for use in patients below 13 years of age.
Discovered by Otsuka Pharmaceutical Co Ltd., aripiprazole is the first and only available dopamine partial agonist and is indicated for the treatment of multiple neurological disorders.
While the exact mechanism of action of aripiprazole is not currently known, aripiprazole is capable of reducing manic symptoms in patients with Bipolar I Disorder.
In Europe and in the United States, the development and commercialisation of aripiprazole is a joint collaboration between Otsuka Pharmaceutical Co, Ltd. and Bristol-Myers Squibb.
About Bipolar Disorder
Bipolar I Disorder (formerly called manic-depression) in adolescents is characterised by the occurrence of one or more manic or mixed (manic-depressive) episodes. This may involve experiencing symptoms such as feeling 'high', having excessive amounts of energy, needing much less sleep than usual, talking very quickly with racing ideas and sometimes severe irritability.
About Otsuka Pharmaceutical Co., Ltd. and Bristol-Myers Squibb
Otsuka Pharmaceutical Co., Ltd. and Bristol-Myers Squibb are collaborative partners in the development and commercialization of aripiprazole in the United States and major European countries.
Founded in 1964, Otsuka Pharmaceutical Co., Ltd. is a global healthcare company with the corporate philosophy: 'Otsuka-people creating new products for better health worldwide.' Otsuka researches, develops, manufactures and markets innovative and original products, with a focus on pharmaceutical products for the treatment of diseases and consumer products for the maintenance of everyday health. Otsuka is committed to being a corporation that creates global value, adhering to the high ethical standards required of a company involved in human health and life, maintaining a dynamic corporate culture, and working in harmony with local communities and the natural environment.
Otsuka Pharmaceutical Co., Ltd. is a wholly owned subsidiary of Otsuka Holdings Co., Ltd., the holding company for the Otsuka Group. The Otsuka Group has business operations in 25 countries and regions around the world. Otsuka Pharmaceutical Co. Ltd. is leading the global research & development in the Central Nervous System domain.
Bristol-Myers Squibb is a global biopharmaceutical company committed to discovering, developing and delivering innovative medicines that help patients prevail over serious diseases.
Information in this news release was current as of the original release date.